Finance & Capital Markets

31. Investing In Early-Stage Oncology With Yosemite's Dan McHugh 3/26/2026

    On this week's episode of the Business of Biotech, Dan McHugh, head of the investment team at Yosemite, explains the San Francisco VC group's approach to investing in early-stage cancer therapeutics and funding academic research through unrestricted grants.

32. Resilient Biopharma Leadership With Ambrx's Dan O'Connor 5/17/2023

    Since Dan O'Connor stepped in as CEO at Ambrx late last year, the company's stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O'Connor is no stranger to overcoming adversity, which we discussed at lenght on this episode of the Business of Biotech.

33. Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham 9/19/2025

    On this week's Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

34. Biotech Angel Investing With Yaniv Sneor 5/21/2025

    On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. The conversation covers how to create a successful pitch, red flags for potential investors, the importance of angel investing syndicates, the sweet spots for exit timelines and funding amounts, and why it still makes sense to invest in biotech over other industry sectors.

35. BoB@JPM: Rick Modi, Affinia Therapeutics 3/5/2025

    The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes to his biotech leadership

36. Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary 4/24/2026

    On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries.

37. CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt 10/25/2023

    What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its contract development and manufacturing outsourcer (CDMO)? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align?

38. Strategic Deals With CinRx's Gavin Samuels, M.D. 3/17/2024

    Gavin Samuels, M.D., found his work as an intensive care physician boring. It wasn't until he left the hospital and entered biopharma that he found his footing. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Dr. Samuels' introspective reflections on biotech dealmaking and negotiations plants this episode firmly on the Business of Biotech podcast highlight reel.

39. Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD 6/28/2023

    Ahmed Hamdy, MD didn’t ask to be the subject of Nathan Vardi's new book​ For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug. In fact, he’d rather not relive that chapter.

40. Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D. 3/20/2023

    On the surface, the merger of Medsenic (a developer of arsenic salt formulations for therapeutic application in inflammatory conditions) and Bone Therapeutics (which develops allogeneic cell therapies for complicated bone fractures) doesn't look obviously synergistic. But Francois Rieger, Ph.D. says that on the scientific level, it's a perfect union, and the veteran biotech founder says the business should always follow the science. The union of the two companies formed BioSenic, which Dr. Regier now serves as CEO. On this week's episode of the Business of Biotech, Dr. Regier shows us the good, the bad, and the ugly of the merger process and shares his philosophy on letting science lead the way, regardless of the analysts' takes.